[A case of primary aldosteronism associated with spironolactone inclusions (author's transl)].
D000236:Adenoma / Q000473:pathology*; D000310:Adrenal Gland Neoplasms / Q000473:pathology*; D000328:Adult; D002191:Canrenoic Acid / Q000009:adverse effects; D005260:Female; D006801:Humans; D006929:Hyperaldosteronism / Q000150:complications*; D002479:Inclusion Bodies / Q000648:ultrastructure*; D010259:Paranoid Disorders / Q000139:chemically induced; D013148:Spironolactone / Q000627:therapeutic use
D013148:Spironolactone; D002191:Canrenoic Acid